Annamycin Shows Over 60% Survival Benefit in Metastatic Pancreatic Cancer Preclinical Models
MBRX sits 43% above its 52-week low of $1.79 on light trading volume (0.4× avg).
Summary
Moleculin Biotech announced new preclinical data for its lead drug candidate, Annamycin, demonstrating significant tumor growth inhibition and a greater than 60% survival benefit in metastatic pancreatic cancer models, presented at AACR 2026.
Key Events · Product Development and Regulatory · MBRX
-
Positive Preclinical Data Presented at AACR 2026
Moleculin Biotech presented new preclinical data for its lead drug candidate, Annamycin, at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting its potential in pancreatic cancer.
-
Significant Survival Benefit in Metastatic Pancreatic Cancer
Liposomal Annamycin (L-ANN) extended median survival by over 60% (29 days vs. 18 days; p=0.0003) in a metastatic pancreatic ductal adenocarcinoma (PDAC) model, alongside significant tumor growth inhibition across multiple models (p<0.001).
-
Enhanced Tumor Penetration and Immune Activation
Pharmacokinetic analyses showed significantly higher tumor and pancreatic tissue accumulation of Annamycin compared to doxorubicin (p<0.0001). L-ANN also induced immune activation, including increased infiltration of CD8+ and CD4+ T cells, suggesting potential for combination therapies.
-
Non-Cardiotoxic Profile Confirmed
Consistent with prior studies, Annamycin demonstrated a favorable safety profile, including the absence of cardiotoxicity, a common limitation of conventional anthracyclines.
Analysis · MBRX · Life Sciences
This 8-K reports highly encouraging preclinical data for Moleculin Biotech's lead drug candidate, Annamycin, in pancreatic cancer, a disease with significant unmet medical need. The demonstration of a greater than 60% extension in median survival in a metastatic model, coupled with significant tumor growth inhibition and enhanced tumor penetration, provides a strong scientific basis for expanding Annamycin's development beyond its current focus in AML. The drug's non-cardiotoxic profile and ability to induce immune activation are key differentiators. This positive news could be particularly impactful for a company of this market capitalization, potentially offsetting recent negative sentiment from significant dilution events (warrant issuance and resale registration) and providing a strong narrative for future capital raises.
At the time of this filing, MBRX was trading at $2.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.3M. The 52-week trading range was $1.79 to $28.61. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.